This Article Full Text Full Text (PDF) Correction (v38,pe76) All Versions of this Article: 38/6/1855    most recent STROKEAHA.106.481556v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Castellanos, M. Articles by Dávalos, A. Search for Related Content PubMed PubMed Citation Articles by Castellanos, M. Articles by Dávalos, A. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Related Collections Acute Cerebral Infarction Emergency treatment of Stroke Computerized tomography and Magnetic Resonance Imaging Intracerebral Hemorrhage Thrombolysis Other Vascular biology

(Stroke. 2007;38:1855.)
© 2007 American Heart Association, Inc.

Original Contributions

Serum Cellular Fibronectin and Matrix Metalloproteinase-9 as Screening Biomarkers for the Prediction of Parenchymal Hematoma After Thrombolytic Therapy in Acute Ischemic Stroke

A Multicenter Confirmatory Study

Mar Castellanos, MD, PhD; Tomás Sobrino, BSc; Mónica Millán, MD; María García, MD, PhD; Juan Arenillas, MD, PhD; Florentino Nombela, MD, PhD; David Brea, BSc; Natalia Perez de la Ossa, MD; Joaquín Serena, MD, PhD; José Vivancos, MD, PhD; José Castillo, MD, PhD Antoni Dávalos, MD, PhD

From the Department of Neurology (M.C., J.S.) and Biostatistics Unit, (M.G.), Hospital Universitari Doctor Josep Trueta, Girona, Spain; the Department of Neurology (T.S., D.B., J.C.), Neurovascular Research Laboratory, Hospital Clínico Universitario, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; the Department of Neurosciences (M.M., J.A., N.P.d.l.O., A.D.), Hospital Universitari Germans Trias i Pujol, Universitat Autónoma de Barcelona, Badalona, Spain; and the Department of Neurology (F.N., J.V.), Hospital Universitario de La Princesa, Madrid, Spain.

Correspondence to Dr Antoni Dávalos, Acute Stroke Unit, Department of Neurosciences, Hospital Germans Trias I Pujol, Universitat Autònoma de Barcelona, Ctra de Canyet s/n, 08916 Badalona, Spain. E-mail adavalos.germanstrias{at}gencat.net

Background and Purpose— Plasma levels of cellular fibronectin (c-Fn) 3.6 µg/mL and of matrix metalloproteinase-9 (MMP-9) 140 ng/mL have been associated with parenchymal hematoma (PH) after treatment with tissue-type plasminogen activator (t-PA) in patients with acute ischemic stroke. In this prospective study, we sought to validate the predictive capacity of the preestablished cutoff values of these biomarkers for PH in a larger series of patients.

Methods— We studied 134 patients treated with t-PA within 3 hours from symptom onset according to the SITS-MOST criteria (median time to infusion, 152 minutes; median National Institutes of Health Stroke Scale score, 14) in 4 university hospitals. Hemorrhagic transformation was classified according to the European-Australasian Acute Stroke Study II definitions on computed tomography scans performed 24 to 36 hours after treatment. Relevant hemorrhagic transformation was defined as hemorrhagic infarction type 2 or any PH. Serum c-Fn and MMP-9 levels were determined by an ELISA om blood samples obtained before treatment.

Results— Cranial computed tomography showed hemorrhagic transformation in 27 patients (20%), hemorrhagic infarction in 15 (type 2 in 8 patients), and PH in 12 patients (symptomatic in 4). Serum c-Fn and MMP-9 concentrations at baseline were significantly higher in patients with relevant hemorrhagic transformation and PH than in those without (all P<0.001). The sensitivity, specificity, and positive and negative predictive values for PH by c-Fn levels 3.6 µg/mL were 100%, 60%, 20%, and 100%, respectively, whereas corresponding values were 92%, 74%, 26%, and 99% for MMP-9 levels 140 ng/mL. When both biomarkers were at levels above the cutoff points, specificity increased to 87% and the positive predictive value increased to 41%.

Conclusions— This prospective study confirmed the high sensitivity and negative predictive value, with retained good specificity, of c-Fn and MMP-9 for the prediction of PH in patients treated with t-PA. Development of faster analytic methods will prove the applicability of these biomarkers in routine clinical practice.

Key Words: stroke • hemorrhage • thrombolytic therapy • metalloproteinases • biomarkers • blood-brain barrier

This article has been cited by other articles:

				O. Moldes, T. Sobrino, M. Millan, M. Castellanos, N. Perez de la Ossa, R. Leira, J. Serena, J. Vivancos, A. Davalos, and J. Castillo High Serum Levels of Endothelin-1 Predict Severe Cerebral Edema in Patients With Acute Ischemic Stroke Treated With t-PA Stroke, July 1, 2008; 39(7): 2006 - 2010. [Abstract] [Full Text] [PDF]